Keywords
Severe Acute Respiratory Syndrome
Mortality
SARS-CoV-2
Intensive Care Unit
Categories
How to Cite
Abstract
Introduction: The SARS-CoV-2 pandemic was an ideal time for depth in cross- immunity study. The study aimed was to determine the possible relate between influenza vaccination and clinical course in hospitalized patients with severe acute respiratory infection (ARI) in a season with low influenza transmission in the community. Patients and methods: Observational historical cohort study of hospitalized patients for severe ARI during the influenza season 2020-21 at Hospital Clinic de Barcelona (HCB). The principal variables were death and admission to the intensive care unit (ICU) with ventilatory support. Multivariate logistic regression was used to explore the association between influenza vaccination and the principal variables. Results: Of the 281 subjects with severe ARF, 45% were vaccinated against influenza. Hospital mortality was 11% and 27% required admission to the ICU with ventilatory support. Influenza vaccination was not significantly associated with mortality or ICU admission with ventilatory support. Increased adjusted mortality was associated with older age (OR: 1.04 [95% CI: 1.01-1.09]), higher comorbidity (OR: 1.56 [95% CI: 1.31-1.91]) and increase in days of admission (OR: 1.03 [95% CI; 1.01-1.05]), and ICU with ventilatory support admission with younger age (OR: 0.96 [95% CI; 0.93-0.99]), radiological abnormalities (OR: 8.61 [95% CI; 2.17-51.62]), and increased in days of admission (OR: 1.15 [95% CI; 1.10-1.22]). Conclusion: Influenza vaccination with low influenza transmission in the community didn’t reflect an effect on clinical outcome of severe ARI in hospitalized patients.
References
Caini S, Spreeuwenberg P, Kusznierz GF, Rudi JM, Owen R, Pennington K, Wangchuk S, Gyeltshen S, Ferreira de Almeida WA, Pessanha Henriques CM, Njouom R, Vernet M-A, Fasce RA, Andrade W, Yu H, Feng L, Yang J, Peng Z, Lara J, Bruno A, de Mora D, de Lozano C, Zambon M, Pebody R, Castillo L, Clara AW, Matute ML, Kosasih H, Puzelli S, Rizzo C, Kadjo HA, Daouda C, Kiyanbekova L, Ospanova A, Mott JA, Emukule GO, Heraud J-M, Razanajatovo NH, Barakat A, el Falaki F, Huang SQ, Lopez L, Balmaseda A, Moreno B, Rodrigues AP, Guiomar R, Ang LW, Lee VJM, Venter M, Cohen C, Badur S, Ciblak MA, Mironenko A, Holubka O, Bresee J, Brammer L, Hoang PVM, Le MTQ, Fleming D, Séblain CE-G, Schellevis F, Paget J. Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014. BMC Infectious Diseases. 2018;18(1).
Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and Cardiovascular Disease. Circulation. 2003;108(22).
RECOMENDACIONES DE VACUNACIÓN FRENTE A LA GRIPE. Ministerio de Sanidad y consumo de España. 2021;.
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2012;12(1).
Epidemiology of Vaccine Preventable Diseases. CDC. 2020;.
Kelly H, Valenciano M. Estimating the effect of influenza vaccines. The Lancet Infectious Diseases. 2012;12(1).
Gripe. WHO/OMS. 2021;.
Weekly influenza updates [Internet]. https://www.ecdc.europa.eu/en/seasonal-influenza/surveillance-and-disease-data/flu- news-europe. Flue News Europe. 2022;.
Falsey A, Walsh E, Hayden F. Rhinovirus and Coronavirus Infection–Associated Hospitalizations among Older Adults. The Journal of Infectious Diseases. 2002;185(9).
Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. Nature Reviews Immunology. 2020;20(6).
Debisarun P, Struycken P, Domínguez-Andrés J, Moorlag S, Taks E, Gössling K. The effect of influenza vaccination on trained immunity: impact on COVID-19. medRxiv. 2020;.
Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, van Driel ML, Nair NS, Jones MA, Thorning S, Conly JM. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews. 2011;.
Chin J, Zhou Y, Chen CL, Lomiguen CM, McClelland S, Lee-Wong M. Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis. Cureus. 2021;.
Belongia EA, Osterholm MT. COVID-19 and flu, a perfect storm. Science. 2020;368(6496).
Fernández Ibáñez JM, Morales Ballesteros M del C, Fernández Anguita MJ, Galindo Andúgar M Ángeles, Arias Arias Ángel, Barberá-Farré JR. Influencia de la vacunación antigripal y la comorbilidad en la evolución de los pacientes hospitalizados por COVID-19. Medicina Clínica. 2022;158(12).
Haq K, McElhaney JE. Immunosenescence: influenza vaccination and the elderly. Current Opinion in Immunology. 2014;29.
Kline KA, Bowdish DM. Infection in an aging population. Current Opinion in Microbiology. 2016;29.
Giannasi S, Venuti M, Midley A, Roux N, Kecskes C, San Román E. Factores de riesgo de mortalidad de los pacientes ancianos en cuidados intensivos sin limitación del esfuerzo de tratamiento. Medicina Intensiva. 2018;42(8).
Fuchs L, Novack V, McLennan S, Celi LA, Baumfeld Y, Park S, Howell MD, Talmor DS. Trends in Severity of Illness on ICU Admission and Mortality among the Elderly. Alazawi W, editor. PLoS ONE. 2014;9(4).
Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, Marchionni L. Influenza Vaccination and COVID-19 Mortality in the USA: An Ecological Study. Vaccines. 2021;9(5).
Castilla J, Martínez-Artola V, Salcedo E, Martínez-Baz I, García Cenoz M, Guevara M, Álvarez N, Irisarri F, Morán J, Barricarte A. Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010–2011: Cohort and case–control study. Vaccine. 2012;30(2).
Casado I, Domínguez A, Toledo D, Chamorro J, Force L, Soldevila N, Astray J, Egurrola M, Godoy P, Mayoral JM, Tamames S, Sanz F, Castilla J. Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert Review of Vaccines. 2016;15(3).
Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. American Journal of Infection Control. 2021;49(6).
Benn CS, Netea MG, Selin LK, Aaby P. A small jab – a big effect: nonspecific immunomodulation by vaccines. Trends in Immunology. 2013;34(9).
Salem ML, El-Hennawy D. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19. Medical Hypotheses. 2020;140.
Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer APS, Daubenberger C, Brentani A. Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. BMJ Evidence-Based Medicine. 2020;26(4).
Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. International Journal of Epidemiology. 2005;35(2).
Tanner AR, Dorey RB, Brendish NJ, Clark TW. Influenza vaccination: protecting the most vulnerable. European Respiratory Review. 2021;30(159).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Sara Herranz-Ulldemolins, Isabel Torà-Rocamora, Anna Llupià, Anna Vilella